Novartis has reached an agreement to buy Regulus Therapeutics and its experimental therapy for autosomal dominant polycystic kidney disease (ADPKD) for $800 million upfront in a deal that could have a ...
You're a DBA, sysadmin, or developer who manages Microsoft SQL Servers. It's your fault if they're down or slow. These tools help you understand what's going on in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback